BACKGROUND: Somatic mutations in the epidermal growth factor receptor (EGFR) are
present in∼ 10% of nonsmall cell lung cancers, and higher in never‐smokers, women, and …

Aims Activating mutations in the gene encoding epidermal growth factor receptor (EGFR)
can confer sensitivity to EGFR tyrosine kinase inhibitors such as gefitinib in patients with …

BACKGROUND Activating mutations in the epidermal growth factor receptor (EGFR) in non–
small cell lung carcinoma (NSCLC) are associated significantly with responsiveness to …

Introduction: To evaluate epidermal growth factor receptor (EGFR) mutation status in lung
adenocarcinoma specimens with different proportions of tumor cells using two methods with …

Tissue heterogeneity of EGFR gene mutation was studied in 10 formalin-fixed paraffin-
embedded (FFPE) samples from four cases that demonstrated EGFR mutations in snap …

Background The authors sought to define clinicopathologic features associated with
mutations of the epidermal growth factor receptor (EGFR) gene in non–small cell lung …

Lung adenocarcinomas responsive to epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors possess EGFR mutations and often increased EGFR copy number. We …

BACKGROUND: The aim of this study was to validate clinical utilization of routinely prepared
cytology specimens for molecular testing to detect EGFR or KRAS mutations in lung cancer …

Activating mutations of the epidermal growth factor receptor (EGFR) in lung tumors are
associated with a dramatic response to tyrosine kinase inhibitors. Therefore, routine analysis …

BACKGROUND. Somatic mutations of the epidermal growth factor receptor (EGFR) gene in
nonsmall‐cell lung cancer (NSCLC) may predict responsiveness to tyrosine kinase …